Home » Stocks » CRTX

Cortexyme, Inc. (CRTX)

Stock Price: $49.91 USD -0.79 (-1.56%)
Updated Oct 28, 2020 2:42 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.47B
Revenue (ttm) n/a
Net Income (ttm) -57.03M
Shares Out 29.49M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $49.91
Previous Close $50.70
Change ($) -0.79
Change (%) -1.56%
Day's Open 49.65
Day's Range 48.25 - 50.61
Day's Volume 34,220
52-Week Range 20.14 - 73.84

More Stats

Market Cap 1.47B
Enterprise Value 1.33B
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.49M
Float 12.02M
EPS (basic) -1.93
EPS (diluted) -1.99
FCF / Share -1.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.67M
Short Ratio 13.21
Short % of Float 13.90%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.01
Revenue n/a
Operating Income -59.65M
Net Income -57.03M
Free Cash Flow -33.34M
Net Cash 144.45M
Net Cash / Share 4.90
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -20.57%
ROE -33.38%
ROIC -54.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(59.43% upside)
Current: $49.91
Target: 79.57
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-39.17-12.12-10.37
Net Income-36.98-12.48-12.24
Shares Outstanding19.033.363.30
Earnings Per Share-1.94-3.71-3.70
Operating Cash Flow-33.28-11.70-9.83
Capital Expenditures-0.06-0.21-0.08
Free Cash Flow-33.33-11.91-9.90
Cash & Equivalents99.8671.727.39
Total Debt--7.17
Net Cash / Debt99.8671.720.22
Book Value115-32.63-20.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cortexyme, Inc.
Country United States
Employees 23
CEO Casey Crawford Lynch

Stock Information

Ticker Symbol CRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRTX
IPO Date May 9, 2019


Cortexyme, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.